ClinicalTrials.gg
CompletedNCT05792917Updated Sep 13, 2023

Bioequivalence Study of Tafolecimab Injections in Chinese Healthy Male Volunteers

A Phase 1 interventional study of tafolecimab (a modified manufacturing process) and tafolecimab (a original manufacturing process) in Healthy Male Subjects, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 1 site in China. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-13.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
166
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Male
01

Study summary

This trial is conducted in China. The purpose of this study is to evaluate the pharmacokinetic similarity of Tafolecimab with different manufacturing process in healthy male subjects. Another purpose is to determine safety, and immunogenicity of sintilimab with different manufacturing process,also to determine Pharmacodynamics of Tafolecimab with different manufacturing process

02

Conditions studied

  • Healthy Male Subjects
03

In context

Lead sponsor

Innovent Biologics (Suzhou) Co. Ltd. is the lead sponsor of 199 studies on the registry; 46 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male subjects between 18 and 65 years of age, inclusive.
  2. Low-density lipoprotein cholesterol (LDL-C) within the range of 1.8 mmol/L to 4.9 mmol/L, inclusive, at screening.
  3. Body weight within the range of 63.0 kilograms (kg) to 75.0 kg, inclusive.
  4. Subjects who are willing maintain current normal diet and physical activity.
  5. Subjects agree to use reliable measures (such as abstinence, sterilization, contraceptives, injectable contraceptive medroxyprogesterone or subcutaneous implant contraception, etc.) during the study period and within 6 months after the study drug infusion.
  6. No history of serious diseases, including (but not limited to) cardiovascular, hepatic, renal, gastrointestinal, psychiatric, neurologic, endocrine, pulmonary, hematological, immune disease.
  7. Subjects voluntarily signed the form and agreed to strictly follow the requirements of this protocol.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who have a history of allergy, or may be allergic to the drug and the related compounds.
  2. Have used the inhibitors of proprotein convertase subtilisin type 9 (PCSK-9).
  3. Have abnormalities identified by Vital signs, physical examination, clinical laboratory tests, 12-lead , or chest X-ray, at screening.
  4. Unwilling to stop any strenuous physical activity (such as weightlifting or long-distance running) within 72 hours before the planned follow-up visit.
  5. History of hospitalization within 1 month before screening, major surgery within 6 months before screening, or other unstable conditions judged by the investigator.
  6. The last dose of the previous investigational product which is chemical drug has been given in less than 1 month before administration.
  7. The last dose of the previous investigational product which is biological drug has been given in less than 3 months before administration.
  8. Have used any drugs (including over-the-counter drugs or prescription drugs), the last medication is less than 14 days or the last medication is less than 5 half-lives of the drug from the administration day (whichever is longer), or are using any drugs.
  9. Have used any traditional Chinese medicines, vitamins or drugs or supplements known to affect lipid metabolism within 30 days before administration.
  10. Have a positive test result of (Human Immunodeficiency Virus, HIV) antibody, virus surface antigen (HBsAg), virus (HCV) antibody or syphilis test at screening.
  11. History of alcohol or drug abuse results within 12 months before screening. Average daily alcohol intake is more than 3 units of alcohol (male) (1 unit≈360mL beer, or 45mL spirits with 40% alcohol content, or 150mL wine), or unwilling to stop drinking 72 hours before administration and throughout the study period, or a positive ethanol breath test at screening, or positive drug screening results by urine at screening.
  12. unable to abstain from smoking, alcohol and caffeinated beverages within 72 hours before administration and throughout the study period.
  13. lost blood, donated blood ≥200 ml within 2 months before screening.
  14. History of organ transplantation or malignant tumor.
  15. Not suitable for this study in the investigator's opinion.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
166 participants (actual)

Study arms

  • Experimental
    tafolecimab (a modified manufacturing process)

    450mg,SC,single dose

    Drug: tafolecimab (a modified manufacturing process)

  • Active comparator
    tafolecimab (a original manufacturing process)

    450mg,SC,single dose

    Drug: tafolecimab (a original manufacturing process)

Interventions

06

What researchers measure

Primary outcomes

  1. Bioequivalence results using the peak serum drug concentration (Cmax) as the judging indicators

    Time frame: up to Day 57

  2. Bioequivalence results using the area under the serum concentration-time curve (AUC0-inf) as the judging indicators

    Time frame: up to Day 57

Secondary outcomes

  1. Other PK parameters: Area under the plasma concentration-time curve (AUClast)

    Time frame: up to Day 57

  2. Other PK parameters: Volume of distribution (V)

    Time frame: up to Day 57

  3. Other PK parameters: elimination half-life (t1/2)

    Time frame: up to Day 57

  4. Number of participants with adverse events, with abnormal vital signs, abnormal physical examination, abnormal laboratory test results and abnormal ECG readings

    Time frame: up to Day 57

  5. The occurrence of Anti-drug Antibody(ADA)

    Time frame: up to Day 57

  6. The occurrence of Neutralizing antibodies Antibody(NAb)

    Time frame: up to Day 57

  7. Percentage Change from baseline in Low Density Lipoprotein choleterol (LDL-C)

    Time frame: up to Day 57

  8. Percentage Change from baseline in Proprotein convertase subtilisin/kexin type 9(PCSK-9)

    Time frame: up to Day 57

07

Study locations

1 site
  • Aerospace Center Hospital
    Beijing, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2023 to primary completion in Mar 2023, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2023
First posted
Mar 31, 2023
StartActual
Mar 6, 2023
Primary completionActual
Mar 26, 2023
CompletionActual
Aug 4, 2023
Last update
Sep 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05792917
Responsible party
Sponsor
First posted
Mar 31, 2023
Start date
Mar 6, 2023
Primary completion
Mar 26, 2023
Completion
Aug 4, 2023
Last update
Sep 13, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tafolecimab

Start the discussion